IVD China last week: Danaher, Fosun, KingMed and Autobio

Danaher and Tongjin Stem Cells Form Strategic Partnership

November 27 – Cytiva, a global pioneer in life sciences under Danaher, signed a strategic cooperation memorandum with Shanghai Tongjin Stem Cell Technology Co., Ltd. The two parties will collaborate to advance efficient purification processes for exosomes derived from stem cells. Additionally, they will actively explore cooperation in the automated production and commercialization of stem cells and exosomes, aiming to drive innovative breakthroughs and synergistic development in China’s biopharmaceutical industry.

Fosun Pharma and ChemPartner Reach Strategic Cooperation

On November 25, Fosun Pharma and ChemPartner held a signing ceremony for a strategic cooperation framework agreement in Shanghai. Li Xiang, Senior Vice President of Fosun Pharma and CEO of the Global R&D Center, stated, “Moving forward, by leveraging ChemPartner’s full-chain R&D service capabilities, we aim to further enhance the efficiency and quality of Fosun Pharma’s drug development across multiple therapeutic areas, accelerate the translation of innovative achievements, and strengthen our competitive edge in the field of innovative medicine. At the same time, this collaboration also sets an exemplary model of ‘innovative entity + service platform’ cooperation for the industry. It will help drive efficient integration of resources across the industry chain, contribute to elevating the overall level of domestic new drug development, and bring more high-quality treatment options to patients.”

Zhengzhou KingMed and Autobio Complete On-Market Transaction of Medical Data

On November 20, the first on-market transaction of a healthcare industry data product in Henan Province was successfully concluded at the Zhengzhou Data Exchange Center. Zhengzhou KingMed, a subsidiary of the KingMed Diagnostics Group, served as the data provider and officially completed the on-market transaction of the data product with Zhengzhou Autobio Engineering Co., Ltd. The data product involved in this transaction is "KingMed Infection Data (Invasive Fungi) Distribution Statistics." This data product integrates detection information for specific types of fungal infections nationwide, reflecting infection prevalence characteristics across different times and regions. It provides scientific data support for the formulation of prevention and control strategies and the optimization of diagnosis and treatment plans for invasive fungal infections.